close
Debiopharm and BIOASTER join forces against infectious diseases
News

Debiopharm and BIOASTER join forces against infectious diseases

Debiopharm and BIOASTER join forces against infectious diseases

The Swiss biopharmaceutical company Debiopharm and BIOASTER, the French Technology Research Institute in infectiology have officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. This relationship will harness BIOASTER’s scientific and technical expertise, including technology platforms, to support Debiopharm’s breakthrough research programs. Their development efforts are expected to accelerate projects towards industrial product readiness. The initial planned project is aimed at exploring further developments of FibroTrap, an easy-to-use sample preparation method for the rapid diagnosis of hard to detect bacteria. Debiopharm’s unique sample preparation technology has already demonstrated excellent sensitivity in the detection of bacteria and yeasts in blood stream infections with the potential to shorten the turn-around-time between sample collection to results from 1-3 days, seen with standard blood culture methods to about 3 hours, including pathogen identification.

Created in 2012, following the French initiative of Technological Research Institutes (TRI),
BIOASTER is a non-for-profit foundation developing a unique technological and innovative
model to support the latest challenges in microbiology. The aim of BIOASTER is to bring together academic, industry and its capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies. Today, BIOASTER has concluded 57 collaborative projects, involving 27 private partners and 29 public partners.

 


COMMENTS ARE OFF THIS POST